TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals Ltd announced a change in the director’s interest, with Michelle Parker acquiring additional options as approved at the company’s 2025 Annual General Meeting. This acquisition of options, valued using financial models, reflects strategic decisions that could impact the company’s future financial performance and stakeholder interests.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd is a company operating in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is engaged in advancing its proprietary platform for targeted therapy and imaging, aiming to improve patient outcomes in oncology and other critical areas.
Average Trading Volume: 2,755,517
Technical Sentiment Signal: Sell
Current Market Cap: A$1.34B
For an in-depth examination of CU6 stock, go to TipRanks’ Overview page.